Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 4c; Guides Lower
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.15 +0.39%
Revenue Growth %: +24.1%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: +24.1%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $68 million versus the consensus estimate of $70.04 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2022 revenue of $240-280 million, versus the consensus of $313.62 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HP shares slide as tech giant forecasts 2027 PC market slump
- Westinghouse said to seek over $50 billion valuation in planned IPO
- HP Inc. projects mid-single-digit PC market decline in 2027
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
